EUVIMEDEUVIMED entdecken
Open Access

Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs

Dan-Yang Shi, Jian-Sheng Lu, Yun-Yun Mao, Fu-Jia Liu, Rong Wang, Peng Du, Shuo Yu, Yun-Zhou Yu, Zhi-Xin Yang

Applied Microbiology and Biotechnology · 2023

DOI: 10.1007/s00253-023-12515-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, 2023. Verfasst von Dan-Yang Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China. Hauptthemen laut MEDLINE: Botulism, Botulinum Toxins, Type A, Antitoxins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Biosafety Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Botulinum neurotoxin (BoNTs; serotypes A, B, E, and F) cause botulism disease in humans, which could be effectively treated using antitoxins. Herein, we established a novel receptor-binding domain (RBD)-based antitoxin using recombinant C terminal heavy chain (Hc) domains of BoNTs as immunogens. Immunization of horses with these recombinant Hc domains allowed the purification and digestion of IgGs from hyper-immune sera to produce high-quality and high-efficiency monovalent botulism antitoxin F(ab')2 against each BoNT (M-BATs). However, these M-BATs could not bind or neutralize other serotypes of BoNTs, and that there were no cross-protective effects among these M-BATs. This suggested the need to prepare tetravalent antitoxins to neutralize the four BoNTs simultaneously. Thus, these M-BATs were formulated into a novel tetravalent botulism antitoxin (T-BAT), in which a 10-ml volume contained 10000 IU of BoNT/A and 5000 IU of BoNT/B, BoNT/E, and BoNT/F antitoxins. The novel antitoxin preparation could prevent and treat the four mixed botulinum neurotoxins simultaneously in vivo, representing strong efficacy in an animal poisoning model. Moreover, these antibodies in T-BAT could bind the RBD, whereas conventional antitoxins based on inactivated toxins mainly bind the light chain or heavy chain translocation domain (HN) and weakly bind the important RBD in current experimental conditions. The high levels of RBD-specific novel antitoxins can efficiently bind the RBD and neutralize natural or recombinant toxins containing this RBD. The findings of the present study experimentally support the use of RBD-specific antitoxins to treat BoNT serotype A, B, E, and F-mediated botulism. This study demonstrated the concept of developing potent novel multivalent antitoxins against all BoNTs or other toxins, using the RBD of these toxins as an alternative antigen to inactivated toxins. KEY POINTS: • Antitoxins based on the receptor-binding domains of botulinum neurotoxins were made. • Novel antitoxin binds RBD; traditional antitoxin mainly binds light chain or HN domain. • A tetravalent antitoxin could prevent and treat the four mixed neurotoxins in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BotulismBotulinum Toxins, Type AAntitoxinsHumansAnimalsHorsesBotulinum AntitoxinNeurotoxinsImmunization

Stichwörter der Autor:innen

Botulinum neurotoxinBotulismImmunotherapyNeutralizing antibodyReceptor-binding domainTetravalent botulism antitoxin

Substanzen

Botulinum AntitoxinBotulinum Toxins, Type AAntitoxinsNeurotoxins

Autor:innen und Institutionen

  • Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China.
  • Tianjin Institute of Environmental & Operational Medicine, Tianjin, 300050, China.
  • Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China. yunzhouyu@163.com.
  • Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China. yy_xiao@126.com.

Förderung

  • Biosafety Research Project

Zitieren

APA

Shi, D. Y., Lu, J. S., Mao, Y. Y., Liu, F. J., Wang, R., Du, P., Yu, S., Yu, Y. Z., & Yang, Z. X. (2023). Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-023-12515-2

Vancouver

Shi DY, Lu JS, Mao YY, Liu FJ, Wang R, Du P, et al. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs. Applied Microbiology and Biotechnology. 2023. doi:10.1007/s00253-023-12515-2

BibTeX
@article{Shi2023,
  author = {Shi, Dan-Yang and Lu, Jian-Sheng and Mao, Yun-Yun and Liu, Fu-Jia and Wang, Rong and Du, Peng and Yu, Shuo and Yu, Yun-Zhou and Yang, Zhi-Xin},
  title = {Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs},
  journal = {Applied Microbiology and Biotechnology},
  year = {2023},
  doi = {10.1007/s00253-023-12515-2}
}
Kostenlos starten →